Back to search
FDAFDA · Food and drugs·Recall number D-0462-2022

Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.

Published January 26, 2022 · Recall initiated: January 5, 2022

Summary

FDA records drug Class I recall D-0462-2022, published January 26, 2022 and initiated January 5, 2022. Recalling firm: Mylan Pharmaceuticals Inc; Status: Terminated; Reported quantity: 73,175 prefilled pens; Lot: Batch # BF20003118, Exp. August 2022. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Missing Label: label missing from some Semglee prefilled pens.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc
Distributor
Nationwide in the USA and Thailand.
Lot
Batch # BF20003118, Exp. August 2022
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505. recalled?

Yes. FDA published recall D-0462-2022 on January 26, 2022. Reported hazard: Labeling: Missing Label: label missing from some Semglee prefilled pens.

What should I do if I have this product?

Voluntary: Firm initiated · Letter